Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

JW Therapeutics to Launch CD-19 CAR-T in China for Lymphoma

publication date: Sep 7, 2021

JW Therapeutics, a Shanghai CAR-T company, was approved to launch its anti-CD-19 CAR-T to treat large B-cell lymphoma in China. Relmacabtagene autoleucel injection (relma-cel) was approved as a third-line therapy for adult patients with relapsed or refractory LBCL. Relma-cel is the first China developed CAR-T product approved for China use and the sixth approved CAR-T product globally. It will be marketed under the trade name Carteyva®. JW is a joint venture of Juno Therapeutics (now a Bristol Myers Squibb company) and WuXi AppTec. More detail....

Stock Symbols: (HK: 2126) (SHA: 603259; HK: 2359)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China